Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 6Neoplasms 1Multiple Endocrine Neoplasia Type 2a 1Lymphoma, Large-Cell, Anaplastic 1Lung Neoplasms 1Lung Diseases 1Central Nervous System Neoplasms 1

Interventions

Biopsy 5X-Rays 4Specimen Handling 4Phantoms, Imaging 4Nuclear Medicine Department, Hospital 4Magnetic Resonance Spectroscopy 4larotrectinib 2erdafitinib 2ensartinib 2ulixertinib 1tipifarnib 1tazemetostat 1selpercatinib 1palbociclib 1olaparib 1niraparib 1ivosidenib 1elacestrant 1cabozantinib 1alectinib 1abemaciclib 1Vincristine 1Vinblastine 1Vemurafenib 1Topotecan 1Temozolomide 1RAD1901 1Methotrexate 1LY3023414 1Induction Chemotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Central Nervous System Neoplasms × alectinib × 30 days × Clear all
NCT04774718 2026-06-04

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors

Hoffmann-La Roche

Phase 1/2 Recruiting
42 enrolled
CNS

Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡